BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32440843)

  • 1. Efficacy and Therapeutic Drug Monitoring of Continuous Beta-Lactam Infusion for Osteoarticular Infections Caused by Fluoroquinolone-Resistant Pseudomonas aeruginosa: A Prospective Cohort Study.
    Gómez-Junyent J; Rigo-Bonnin R; Benavent E; Soldevila L; Padullés A; Cabo X; Tubau F; Ariza J; Murillo O
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):587-599. PubMed ID: 32440843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus β-lactams.
    Ribera A; Benavent E; Lora-Tamayo J; Tubau F; Pedrero S; Cabo X; Ariza J; Murillo O
    J Antimicrob Chemother; 2015 Dec; 70(12):3357-65. PubMed ID: 26419763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical.
    Sorlí L; Luque S; Li J; Campillo N; Danés M; Montero M; Segura C; Grau S; Horcajada JP
    J Infect; 2019 Sep; 79(3):253-261. PubMed ID: 31265867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-lactams in continuous infusion for Gram-negative bacilli osteoarticular infections: an easy method for clinical use.
    Ribera A; Soldevila L; Rigo-Bonnin R; Tubau F; Padullés A; Gómez-Junyent J; Ariza J; Murillo O
    Infection; 2018 Apr; 46(2):239-244. PubMed ID: 29363049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
    Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.
    Moriyama B; Henning SA; Childs R; Holland SM; Anderson VL; Morris JC; Wilson WH; Drusano GL; Walsh TJ
    Ann Pharmacother; 2010 May; 44(5):929-35. PubMed ID: 20371747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study.
    Navarrete-Rouco ME; Luque S; Sorlí L; Benítez-Cano A; Roberts JA; Grau S
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):561-566. PubMed ID: 35657580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients.
    Hachem RY; Chemaly RF; Ahmar CA; Jiang Y; Boktour MR; Rjaili GA; Bodey GP; Raad II
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1905-11. PubMed ID: 17387153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.
    Koomanachai P; Tiengrim S; Kiratisin P; Thamlikitkul V
    Int J Infect Dis; 2007 Sep; 11(5):402-6. PubMed ID: 17291803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.
    Lu Q; Luo R; Bodin L; Yang J; Zahr N; Aubry A; Golmard JL; Rouby JJ;
    Anesthesiology; 2012 Dec; 117(6):1335-47. PubMed ID: 23132092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Pharmacodynamics of Prolonged Infusion β-Lactams for the Treatment of Pseudomonas aeruginosa Infections: A Systematic Review.
    Thabit AK; Hobbs ALV; Guzman OE; Shea KM
    Clin Ther; 2019 Nov; 41(11):2397-2415.e8. PubMed ID: 31679822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa.
    Sorlí L; Luque S; Segura C; Campillo N; Montero M; Esteve E; Herrera S; Benito N; Alvarez-Lerma F; Grau S; Horcajada JP
    BMC Infect Dis; 2017 Jan; 17(1):11. PubMed ID: 28056821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa.
    Naesens R; Vlieghe E; Verbrugghe W; Jorens P; Ieven M
    BMC Infect Dis; 2011 Nov; 11():317. PubMed ID: 22085766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes, molecular epidemiology and resistance mechanisms of multidrug-resistant
    Sid Ahmed MA; Hamid JM; Husain AA; Hadi HA; Skariah S; Sultan AA; Ibrahim EB; Al Khal AL; Soderquist B; Jass J; Omrani AS
    Ann Med; 2021 Dec; 53(1):2345-2353. PubMed ID: 34882052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome.
    Fernandes M; Vira D; Medikonda R; Kumar N
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):315-22. PubMed ID: 26537122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm.
    Gómez-Junyent J; Murillo O; Yu HH; Azad MAK; Wickremasinghe H; Rigo-Bonnin R; Benavent E; Ariza J; Li J
    Int J Antimicrob Agents; 2021 Feb; 57(2):106246. PubMed ID: 33253904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
    Montero MM; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Segura C; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    J Glob Antimicrob Resist; 2019 Sep; 18():37-44. PubMed ID: 31154007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.